Please upgrade your browser.
New patient information is now available on Cancer.Net about the coverage of costs for research study participation under the Affordable Care Act (ACA), which now requires health insurance companies to cover routine costs associated with approved clinical trials.
Despite large gains in health over the past few decades, the distribution of health risks worldwide remains extremely and unacceptably uneven.
Choroidal metastases generally appear as a solitary, yellow- or orange-colored mass in the macula or perimacular region of the eye. In an analysis of 520 eyes with uveal metastasis, the tumor appeared as a solitary mass (71%) with mean basal dimension of 9 mm and mean thickness of 3 mm.1 In that analysis, associated findings included subretinal fluid (73%) and retinal pigment epithelial alterations (57%). Hemorrhage is an unusual finding with choroidal metastatic disease. Single case reports have highlighted this rare association.
The SWITCH trial makes it official: it makes no difference whether patients with metastatic renal cell carcinoma (mRCC) first start on sorafenib and then switch to sunitinib upon progression or vice versa.
Prognostic Tools that Help Make Sense of Localized RCC Heterogeneity, Guide the Decision-Making Process
One of the greatest challenges clinicians face in treating patients with small renal masses is to make sense of tumor heterogeneity and determine how best to treat these individuals.
Left ventricular infiltration from thyroid papillary carcinoma mimicking the electrocardiographic changes of acute myocardial infarction
No abstract (ahead of publication)
Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management
Purpose Approximately 5% to 8% of renal cell carcinoma (RCC) is hereditary. No guidelines exist for patient selection for RCC germline mutation testing. We evaluate how age of onset could indicate the need for germline mutation testing for detection of inherited forms of kidney cancer.
Obesity increases risk for clear-cell renal cell carcinoma, but obese patients appear to experience longer survival than nonobese patients. Why the paradox?
Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France
Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA
|Powered by NeonCRM|